feedback

Course Director

Johanna C. Bendell, MD
Johanna C. Bendell, MD

Sarah Cannon Research Institute
Nashville, Tennessee

Faculty

Tanios Bekaii-Saab
Tanios Bekaii-Saab, MD, FACP

Mayo Clinic College of Medicine and Science
Mayo Clinic Cancer Center
Phoenix, Arizona

Michael J. Pishvaian
Michael J. Pishvaian, MD, PhD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Rachna T. Shroff
Rachna T. Shroff, MD, MS

University of Arizona Cancer Center
Tucson, Arizona

Accredited by

Medical Learning Institute, Inc.

View Activity Materials

Activity Description

Innovations in the management of pancreatic cancer have increased hope for patients with this aggressive malignancy. New and promising treatment advances include novel chemotherapy platforms, such as gemcitabine/nab-paclitaxel and nanoliposomal irinotecan–based regimens; targeted systemic approaches, including PARP inhibitors, stroma-targeting agents, and immunotherapies; and other novel modalities, such as tumor treating fields. Modern chemotherapy regimens have improved outcomes for patients in the first- and second-line advanced settings, while practice-changing data on targeted strategies continue to emerge, offering more personalized prospective treatment plans. How has the treatment of pancreatic cancer changed in the first- and second-line metastatic settings? What are the roles of mutation testing and PARP inhibitors in the frontline maintenance setting? What novel solutions are on the horizon for unmet clinical needs in locally advanced and metastatic settings?

Through collaboration with Let’s Win, an affiliate of the Lustgarten Foundation, this PeerView Live on-demand activity answers these key questions and others with a “How I Think, How I Treat” educational design, providing a personal look at the way experts consider important new and emerging data while navigating the current pancreatic cancer treatment landscape to enhance patient care and outcomes.

Target Audience

This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of patients with pancreatic cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Review the latest clinical evidence on use of novel chemotherapy platforms, immunotherapy, PARP inhibitors, stromal-targeting agents, and tumor treating field therapy, among others, for pancreatic cancer
  • Examine the emerging role of PARP inhibitors in frontline, maintenance setting for patients with BRCA-mutant pancreatic cancer
  • Summarize ongoing clinical trials investigating innovative therapies, including immunotherapy, tumor treating fields, combinations with chemotherapy platforms, among others, for patients with pancreatic cancer
  • Recommend optimal treatment plans, including the enrollment of clinical trials, across multiple lines of therapy for patients with advanced pancreatic cancer based on validated evidence, guideline recommendations, and disease- and patient-specific factors

Providership, Credit, and Support


This CME/MOC activity is jointly provided by Medical Learning Institute, Inc., Let’s Win, and PVI, PeerView Institute for Medical Education. Let’s Win is an affiliate of the Lustgarten Foundation.

This activity is supported by independent educational grants from AstraZeneca, Celgene Corporation, Halozyme Therapeutics, Ipsen Biopharmaceuticals, Inc., Merck & Co., Inc., and Novocure.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Learning Institute, Inc., Let’s Win, and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Faculty Disclosures

Chair
Johanna C. Bendell, MD
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Nashville, Tennessee

Johanna C. Bendell , MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Agios, Inc.; Amgen, Inc.; Apexigen; Arch Oncology; ARMO BioSciences; Array BioPharma; AstraZeneca; Bayer Corporation; BeiGene; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Celgene Corporation; Continuum Clinical; Cyteir; Daiichi Sankyo Company, Limited; Eli Lilly and Company; Five Prime Therapeutics, Inc.; FORMA Therapeutics; Genentech, Inc./F. Hoffmann-La Roche Ltd; Gilead; GlaxoSmithKline; Incyte Corporation; Innate Pharma; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Leap Therapeutics, Inc.; MacroGenics, Inc.; MedImmune; Merck & Co., Inc.; Merrimack; Moderna, Inc.; Molecular Partners; Novartis Pharmaceuticals Corporation; OncoGenex Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; PhoenixBio Co., Ltd.; Prelude Therapeutics; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.; Taiho Oncology, Inc.; TG Therapeutics, Inc.; Tanabe Research Laboratories; Tolero Pharmaceuticals; Torque Pharmaceuticals Pvt Ltd; Tizona Therapeutics, Inc.; and Translational Drug Development (TD2).
Grant/Research Support from AbbVie Inc.; Acerta Pharma; ADC Therapeutics; Agios, Inc.; Amgen, Inc.; Apexigen; Arch Oncology; Arcus Biosciences; ARMO BioSciences; Array BioPharma; Arrys Therapeutics Inc.; AstraZeneca; Bayer Corporation; Bellicum Pharmaceuticals, Inc.; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Biomedical; Bristol-Myers Squibb; Calithera; Celgene Corporation; Celldex Therapeutics; CytomX Therapeutics, Inc.; Daiichi Sankyo Company, Limited; Effector Therapeutics, Inc.; Eisai Inc.; Eli Lilly and Company; EMD Serono, Inc.; Evelo Biosciences, Inc.; Five Prime Therapeutics, Inc.; FORMA Therapeutics; Forty Seven Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd; Gilead; GlaxoSmithKline; Gossamer Bio; Harpoon Therapeutics; ImClone Systems Incorporated; Incyte Corporation; Innate Pharma; Ipsen Pharma; Jacobio Pharmaceuticals; Kolltan Pharmaceuticals Inc.; Leap Therapeutics, Inc.; MacroGenics, Inc.; Marshall Edwards; MedImmune; Merck & Co., Inc.; Merrimack; Mersana Therapeutics Inc.; Merus; Millennium Pharmaceuticals, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Novocure; OncoGenex Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; Onyx Pharmaceuticals; Pfizer Inc.; Pieris Pharmaceuticals; Prelude Therapeutics; Rgenix; sanofi-aventis U.S. LLC; Sierra Oncology, Inc.; SynDevRx Inc.; Taiho Oncology, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Tarveda Therapeutics; TG Therapeutics, Inc.;Tracon Pharmaceuticals, Inc.; Tyrogenex Inc.; Unum Therapeutics Inc.; and Vyriad.
Other Financial or Material Support from ARMO BioSciences; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Celgene Corporation; Eli Lilly and Company; FORMA Therapeutics; Genentech, Inc./F. Hoffmann-La Roche Ltd; Gilead; Ipsen Pharma; MedImmune; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoGenex Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; and Taiho Oncology, Inc. in the form of food/beverage/travel.

Faculty
Tanios Bekaii-Saab, MD, FACP
Professor of Medicine, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center
Consultant, Mayo Clinic AZ, USA
Consortium Chair, (ACCRU) Research Consortium
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Array BioPharma; Bayer Corporation; Genentech, Inc.; Incyte Corporation; and Ipsen Biopharmaceuticals, Inc.
Grant/Research Support from Bayer Corporation; Eli Lilly and Company; and Ipsen Biopharmaceuticals, Inc.
Other Financial or Material Support from 1Globe Health Institute; AstraZeneca; Eli Lilly and Company; Exelixis, Inc.; Merck & Co., Inc.; and Pancreatic Cancer Action Network; as a part of the Internal Displacement Monitoring Centre.

Michael J. Pishvaian, MD, PhD
Co-director for Clinical Research at the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research
Associate Professor, Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Michael J. Pishvaian, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca/MedImmune; Halozyme, Inc.; Merck & Co., Inc.; and Perthera, Inc.
Grant/Research Support from ARMO BioSciences, Inc.; Bavarian Nordic; Bayer Corporation; Bristol-Myers Squibb; Celgene Corporation; Celldex Therapeutics; Curegenix Inc.; FibroGen, Inc.; Genentech, Inc.; Halozyme, Inc.; Karyopharm; MedImmune; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pharmacyclics LLC; Regeneron; and TESARO, Inc. Funding goes to Institution.
Speakers Bureau participant with Caris Life Sciences and Sirtex Medical Inc.

Rachna T. Shroff, MD, MS
Chief, Section of GI Medical Oncology
Associate Professor of Medicine
Division of Hematology/Oncology
University of Arizona Cancer Center
Director, University of Arizona Cancer Center Clinical Trials Office
Tucson, Arizona

Rachna T. Shroff, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Agios, Inc.; Clovis Oncology; Debiopharm Group; Exelixis, Inc.; Merck & Co., Inc.; QED Therapeutics; and Seattle Genetics.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, PVI, PeerView Institute for Medical Education, and Let's Win, joint providers, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Shaina Rozell, MD, MPH
Janice Trainor-Tellier, MSN, RN

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

About This CME/MOC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.